目的探讨全氟化合物(PFAAs)暴露与儿童哮喘及Th1型细胞因子[白细胞介素(IL)-2、γ干扰素(IFN-γ]和Th2型细胞因子(IL-4、IL-5)分泌水平的关系。方法选择231例医院就诊的哮喘儿童作为病例组,来自社区的225例正常儿童作为对照组...目的探讨全氟化合物(PFAAs)暴露与儿童哮喘及Th1型细胞因子[白细胞介素(IL)-2、γ干扰素(IFN-γ]和Th2型细胞因子(IL-4、IL-5)分泌水平的关系。方法选择231例医院就诊的哮喘儿童作为病例组,来自社区的225例正常儿童作为对照组。采用双抗体ELISA试剂盒检测儿童血清中细胞因子IL-2、IFN-γ、IL-4、IL-5的分泌水平;高效液相色谱仪分析血清中全氟辛烷磺酸(PFOS)和全氟辛酸(PFOA)的水平。结果哮喘儿童机体PFOS(33.9μg/L掷.28.9μg/L)和PFOA(1.2μg/L vs .0.5μg/L)暴露负荷显著高于对照组儿童,且随着机体PFAAs的增高,儿童患哮喘的风险呈增高趋势。对哮喘儿童而言,血清PFAAs水平与Th1型细胞因子(IL-2、IFN-γ)存在显著负相关关系,而与Th2型细胞因子(IL-4、IL-5)呈正相关关系。结论PFOS暴露可诱导机体免疫应答平衡紊乱,向Th2型免疫应答极化。展开更多
Objective To investigate the relationship between the expression of Th1/Th2 type cytokines and the effect of interferon-α therapy. Methods Th1/Th2 type cytokines were assayed by enzyme-linked immunosorbent assay (E...Objective To investigate the relationship between the expression of Th1/Th2 type cytokines and the effect of interferon-α therapy. Methods Th1/Th2 type cytokines were assayed by enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) on 23 patients with chronic hepatitis B who were treated with interferon-α.Results Levels of IFN-γ in the supernatant of peripheral blood mononuclear cells (PBMC) cultures from the patients with hepatitis B were slightly lower than those of controls (P=0.07). However, the levels of IL-4 were higher than those of controls (P=0.01). Cytokines measurements during IFN-α treatment showed a trend to decreaseing levels of IL-4 at 4, 12, and 24 weeks. Levels of IFN-γ were slightly increased following IFN-α treatment (P=0.09). In patients with a complete response to IFN-α, the levels of IFN-γ were higher at 24 weeks following IFN-α treatment than that of pre-treatment (P=0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P=0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant. Conclusion The expression of Th2 type cytokines is predominant in patients with chronic hepatitis B. Interferon-α therapy can modulate the balance of Th1/Th2 type cytokines, and this is related to its clinical effect. Levels of Th1/Th2 type cytokines could be a predictor of clinical response during Interferon -α treatment.展开更多
文摘目的探讨全氟化合物(PFAAs)暴露与儿童哮喘及Th1型细胞因子[白细胞介素(IL)-2、γ干扰素(IFN-γ]和Th2型细胞因子(IL-4、IL-5)分泌水平的关系。方法选择231例医院就诊的哮喘儿童作为病例组,来自社区的225例正常儿童作为对照组。采用双抗体ELISA试剂盒检测儿童血清中细胞因子IL-2、IFN-γ、IL-4、IL-5的分泌水平;高效液相色谱仪分析血清中全氟辛烷磺酸(PFOS)和全氟辛酸(PFOA)的水平。结果哮喘儿童机体PFOS(33.9μg/L掷.28.9μg/L)和PFOA(1.2μg/L vs .0.5μg/L)暴露负荷显著高于对照组儿童,且随着机体PFAAs的增高,儿童患哮喘的风险呈增高趋势。对哮喘儿童而言,血清PFAAs水平与Th1型细胞因子(IL-2、IFN-γ)存在显著负相关关系,而与Th2型细胞因子(IL-4、IL-5)呈正相关关系。结论PFOS暴露可诱导机体免疫应答平衡紊乱,向Th2型免疫应答极化。
文摘Objective To investigate the relationship between the expression of Th1/Th2 type cytokines and the effect of interferon-α therapy. Methods Th1/Th2 type cytokines were assayed by enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) on 23 patients with chronic hepatitis B who were treated with interferon-α.Results Levels of IFN-γ in the supernatant of peripheral blood mononuclear cells (PBMC) cultures from the patients with hepatitis B were slightly lower than those of controls (P=0.07). However, the levels of IL-4 were higher than those of controls (P=0.01). Cytokines measurements during IFN-α treatment showed a trend to decreaseing levels of IL-4 at 4, 12, and 24 weeks. Levels of IFN-γ were slightly increased following IFN-α treatment (P=0.09). In patients with a complete response to IFN-α, the levels of IFN-γ were higher at 24 weeks following IFN-α treatment than that of pre-treatment (P=0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P=0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant. Conclusion The expression of Th2 type cytokines is predominant in patients with chronic hepatitis B. Interferon-α therapy can modulate the balance of Th1/Th2 type cytokines, and this is related to its clinical effect. Levels of Th1/Th2 type cytokines could be a predictor of clinical response during Interferon -α treatment.